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Abstract
Neurocysticercosis (NCC) is a major cause of epilepsy in regions where pigs are free-ranging and hygiene is poor. Pork
production is expected to increase in the next decade in sub-Saharan Africa, hence NCC will likely become more prevalent.
In this study, people with epilepsy (PWE, n=212) were followed up 28.6 months after diagnosis of epilepsy. CT scans were
performed, and serum and cerebrospinal fluid (CSF) of selected PWE were analysed. We compared the demographic data,
clinical characteristics, and associated risk factors of PWE with and without NCC. PWE with NCC (n=35) were more likely to
be older at first seizure (24.3 vs. 16.3 years, p=0.097), consumed more pork (97.1% vs. 73.6%, p=0.001), and were more
often a member of the Iraqw tribe (94.3% vs. 67.8%, p=0.005) than PWE without NCC (n=177). PWE and NCC who were
compliant with anti-epileptic medications had a significantly higher reduction of seizures (98.6% vs. 89.2%, p=0.046). Other
characteristics such as gender, seizure frequency, compliance, past medical history, close contact with pigs, use of latrines
and family history of seizures did not differ significantly between the two groups. The number of NCC lesions and active
NCC lesions were significantly associated with a positive antibody result. The electroimmunotransfer blot, developed by the
Centers for Disease Control and Prevention, was more sensitive than a commercial western blot, especially in PWE and
cerebral calcifications. This is the first study to systematically compare the clinical characteristics of PWE due to NCC or other
causes and to explore the utility of two different antibody tests for diagnosis of NCC in sub-Saharan Africa.
Citation: Blocher J, Schmutzhard E, Wilkins PP, Gupton PN, Schaffert M, et al. (2011) A Cross-Sectional Study of People with Epilepsy and Neurocysticercosis in
Tanzania: Clinical Characteristics and Diagnostic Approaches. PLoS Negl Trop Dis 5(6): e1185. doi:10.1371/journal.pntd.0001185
Editor: Ana Flisser, Universidad Nacional Auto ´noma de Me ´xico, Me ´xico
Received October 28, 2010; Accepted April 14, 2011; Published June 7, 2011
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: The study was supported by the Savoy Epilepsy Foundation, Quebec, Canada and ASW was supported by the Centre for International Migration,
Frankfurt, Germany. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: joachim.blocher@med.uni-goettingen.de
Introduction
Epilepsy in Low Income Countries
Epilepsy is one of the most common neurological disorders
worldwide. More than 80% of people with epilepsy (PWE) live in
low income countries [1] and more than 75% of them are not
treated sufficiently [2]. The prevalence of epilepsy is two to ten
times higher and the incidence rate twice that of high income
countries [3]. In northern Tanzania, where our study took place,
recent results indicate a prevalence of 11.2 per 1000 [4]. One
important step towards reducing the burden of epilepsy is to assess
its prevalence, causes and risk factors in resource poor countries.
Cysticercosis
According to the International League Against Epilepsy (ILAE),
neurocysticercosis (NCC) is a growing problem in tropical countries
and increasingly recognized as a leading cause of epilepsy [5–8]. A
recent meta-analysis including only studies from Africa revealed a
highly significant association between cysticercosis and epilepsy,
suggesting that NCC is a major cause of epilepsy in Africa [9]. In
endemic countries, NCC is the cause of epilepsy in more than a
quarter of PWE [10]. Worldwide, NCC is the most common
parasitic disease of the nervous system [1]. Cysticercosis occurs
when humans become infected with Taenia solium eggs and develop
the larval stage. Typical clinical manifestations of NCC are epileptic
seizures, which are caused by the cysticerci themselves and by the
host’s immune response [11].
Pig farming has increased considerably in East and South
Africa, especially in rural, low income, smallholder communities
[12]. Thus cysticercosis may represent a growing problem,
especially in rural areas like our study area, where proper meat
inspection does not exist and lack of health education and hygiene
is common [11]. The costs of cysticercosis are considerable.
Carabin et al. calculated a loss of 34.2 million US-Dollars caused
by cysticercosis for the Eastern Cape Province in South Africa with
7 million inhabitants in 2004 [13].
Diagnostic accuracy is the key to identify people with NCC and
to treat them according to established guidelines. In most low
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readily available. Diagnosis is established based on medical
history, physical examination and, if present, laboratory testing.
In our study, we present clinical details of PWE with and without
NCC, results of neuroimaging and of two different antibody tests
for cysticercosis in an area of northern Tanzania, which only
recently has been shown to be highly endemic for cysticercosis
[14,15].
Methods
Ethical Considerations
The project was ethically cleared by The National Institute for
Medical Research (NIMR), Tanzania. Patients were informed
about the risks and benefits of participating in the study, computed
tomography (CT) examination and necessary treatments. Written
informed consent was obtained from all participants. Patients
received free anti-epileptic and, if necessary, anthelmintic
treatment according to national guidelines during and after the
study. The shipment of samples to the Centers for Disease Control
and Prevention, in Atlanta, GA (CDC), was in accordance with
institutional review boards and material transfer agreements
between Haydom Lutheran Hospital (HLH), CDC, NIMR and
the Medical University Innsbruck.
Study Site
The study was conducted at HLH, which is situated in a remote
rural area of northern Tanzania. The total immediate catchment
area of the hospital comprises 316,168 people [16]. In 2002, one of
the authors (ASW) established a clinic for PWE at HLH, which
nowadays cares for more than 400 PWE. The implementation of
CT scanning in 2005 further improved diagnostic capacity for
people with epileptic seizures/epilepsy. The main tribes in the
study area are Iraqw, Datoga and Bantu tribes. The Iraqw and
Bantu are agro-pastoralists, while the Datoga traditionally have
been nomadic pastoralists, though many are now less nomadic and
more agricultural.
Recruitment of People with Epilepsy
In a former project between August 2002 and October 2004,
our research group identified and characterised 346 people with
epileptic seizures [17]. Demographic and clinical characteristics,
psychosocial as well as sociocultural aspects and the pattern of
injuries were evaluated. Epilepsy was defined as two or more
afebrile seizures unrelated to acute metabolic disorders or to
withdrawal of drugs or alcohol [18] and grouped according to a
classification developed for resource poor countries [19], which is
based on the ILAE classification for epileptic seizures [20]. The
diagnosis was based on seizure semiology, past and present
medical history, other associated risk factors and physical
examination only. Imaging or EEG was not available at time of
diagnosis of epilepsy. Of these 346 people with epileptic seizures
212 participated in the CT study. Due to ethical reasons children
younger than ten years at time of diagnosis of epilepsy and
pregnant women were excluded. For more details on inclusion and
exclusion criteria see Figure 1.
Study Protocol
All participating PWE were interviewed by a doctor in training
and two local nurses using a follow up protocol, which had been
validated in a previous study [17]. Additional questions related to
NCC were added. Compliance with treatment was assessed by
checking regular attendance at HLH and, if attending regularly,
calculating the number of tablets that should have remained since
the last appointment and counter-checking it with the actual
number of tablets.
Neuroimaging and Serodiagnosis
All 212 PWE underwent CT examination. The CT machine
was a Toshiba Auklet Single Slice Spiral CT. The thickness of
slices was 5 mm in the posterior cranial fossa and 10 mm for the
rest. Intravenous contrast medium was applied in all patients. The
pictures were saved digitally and sent to Innsbruck, where a
neuroradiologist reviewed all scans. A detailed description of the
results on neuroimaging has recently been published [15].
CT based diagnosis of NCC was divided into three groups:
definite NCC lesions, lesions highly suggestive of, and those
compatible with NCC. Definite NCC lesions were cystic lesions
showing the scolex. Any cystic lesion without a visible scolex, single
or multiple ring or nodular enhancing lesions and parenchymal
brain calcifications were categorized as lesions highly suggestive of
NCC [21,22]. Any pathology that might be caused by NCC such
as hydrocephalus or enhancement of the leptomeninges was
considered compatible [21,22], single calcifications in parenchy-
mal brain were also considered compatible. Active NCC was
defined as any cystic lesions or lesions with ring enhancement.
Parenchymal calcifications were classified as inactive [23,24].
Due to financial restrictions only part of the collected serum
samples (20 of PWE with either highly suggestive or definite NCC
lesions and 20 of PWE without NCC lesions on CT scan) and all
11 CSF samples of PWE with highly suggestive or definite NCC
lesions on CT scan were analysed with a commercially available
western blot (CWB) for cysticercosis (LDBio, Lyon, France) [25–
27] at the Department for Medical Parasitology, Institute of
Specific Prophylaxis and Tropical Medicine, Medical University
Vienna, Austria. The antigen used in this test was prepared from
T. solium larvae (cysticerci). At a later stage of the project all
collected serum samples (28 of PWE with either highly suggestive
or definite NCC lesions, 7 of PWE with compatible NCC lesions
and 46 of PWE without NCC lesions on CT scan) and CSF
samples (11 CSF samples of PWE with highly suggestive or definite
NCC lesions on CT scan) were tested at the CDC using the
Author Summary
Neurocysticercosis, a preventable and treatable disease, is
one of the main causes of epilepsy in low income
countries. In these countries, the diagnosis of epilepsy is
often based on clinical presentation and interviews as
neuroimaging is rarely available. It is crucial to distinguish
people with epilepsy due to neurocysticercosis from other
people with epilepsy by clinical symptoms and/or serolo-
gy, because the former warrants a specific approach both
in terms of diagnosis and treatment. The authors
compared the demographic and clinical data of the two
groups and found that people with epilepsy due to
neurocysticercosis are older, more likely to consume pork,
and respond better to anti-epileptic treatment. Addition-
ally, the authors compared two antibody tests for
cysticercosis with computed tomography images, which
showed a higher sensitivity of the CDC electroimmuno-
transfer blot compared to a commercial western blot. The
number of neurocysticercosis lesions was significantly
associated with a positive antibody result in both tests.
In summary, this research describes clinical characteristics
of people with epilepsy and neurocysticercosis and
assesses the usefulness of two immunoblots in those
patients. This has implications not only for the diagnosis of
neurocysticercosis in low income countries, but also for
future epidemiological research.
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EITB). The CDC EITB was performed as described previously
[28].
Diagnostic Criteria of Neurocysticercosis
The criteria proposed by Del Brutto et al. were used for diagnosis
of clinical NCC. A set of defined absolute, major and minor criteria,
based on clinical signs and symptoms, neuroimaging, detection of
antibodies and epidemiological considerations, were used to
establish degrees of certainty for diagnosis, which are classified as
definitive and probable NCC [21,22]. In our study, we compared
PWE with definitive or probable NCC to those without NCC. A
positive serological result in both tests (CWB and CDC EITB) was
only considered once as a criterion for the diagnosis of NCC.
Statistical Analysis
All data were entered in a SPSS-database. Statistical analysis
was performed with the same program. Since all numeric variables
had a non-parametric distribution, differences between PWE with
and without NCC were tested for significance with Mann-
Whitney-U test. Categorical data were tested with Fisher’s exact
test. McNemar’s test was applied to data from samples that were
analysed with both antibody tests in order to find significant
differences. A p-value lower than 0.05 was regarded as significant.
Insufficient answers were left as missing data in the database and
were excluded from statistical analysis. Hence the number of
people within a specific category might differ from the total
number of examined PWE (n=212).
The reduction of seizure frequency was calculated by dividing
the seizure frequency after treatment in 2006 by the seizure
frequency before treatment. People with no seizures in 2006 had a
reduction of 100 percent. People with an increased number of
seizures had zero percent reduction.
Results
Demographic Details
The median duration of epilepsy from the day of diagnosis until
the day of the follow up for this study was 28.6 months. The range
was between 19.3 and 47.7 months. In our cohort of 212 PWE, 35
(16.5%) satisfied the diagnostic criteria for either probable or
definitive NCC. The main demographic findings are shown in
Table 1.
People with active NCC lesions (n=6) with an average age of
47.7 years (SD 23.4) were significantly older than people with
inactive NCC (n=25) with an average age of 25.2 years ((SD
15.5); Mann-Whitney-U, p=0.015). Also, the mean age of PWE
with active NCC at first seizure (41.2 years (SD 23.0)) was
significantly higher when compared to PWE with inactive NCC
(16.8 years (SD 16.5); Mann-Whitney-U, p=0.007).
Figure 1. Flow chart for the recruitment of patients. For more details see Methods.
doi:10.1371/journal.pntd.0001185.g001
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neurocysticercosis.
Characteristics PWE with NCC PWE without NCC Total
Age at examination day in years N 35 177 212
p=0.530 Mean (SD) 32.5 (20.6) 27.3 (12.7) 28.2 (14.4)
Median (range) 22 (13–83) 24 (11–72) 24 (11–83)
Age at first seizure in years N 35 176 211
p=0.097 Mean (SD) 24.3 (22.0) 16.3 (12.2) 17.7 (14.5)
Median (range) 17 (0.1–77) 14 (0.3–64) 14 (0.1–77)
Gender Male N (%) 21 (60.0) 87 (49.2) 108 (50.9)
p=0.270 Female N (%) 14 (40.0) 90 (50.8) 104 (49.1)
Tribe Iraqw N (%) 33 (94.3) 120 (67.8) 153 (72.2)
p=0.005 Datoga N (%) 2 (5.7) 27 (15.3) 29 (13.7)
Bantu tribes N (%) 0 (0.0) 28 (15.8) 28 (13.2)
Other N (%) 0 (0.0) 2 (1.1) 2 (0.9)
Educational level None N (%) 14 (40.0) 53 (30.1) 67 (31.8)
p=0.734 Less than 7 years N (%) 9 (25.7) 49 (27.8) 58 (27.5)
Primary school (7 years) N (%) 12 (34.3) 68 (38.6) 80 (37.9)
7–11 years N (%) 0 (0.0) 1 (0.6) 1 (0.5)
Secondary school (11 years) N (%) 0 (0.0) 5 (2.8) 5 (2.4)
Type of seizure
1) Gwa N (%) 15 (42.9) 100 (56.5) 115 (54.2)
p=0.461 Gfs N (%) 7 (20.0) 33 (18.6) 40 (18.9)
Goa N (%) 8 (22.9) 22 (12.4) 30 (14.2)
Gbd N (%) 2 (5.7) 11(6.2) 13 (6.1)
Tt N (%) 3 (8.6) 9 (5.1) 12 (5.7)
U N (%) 0 (0.0) 2 (1.1) 2 (0.9)
Frequency of seizures / month before Tx N 26 153 179
p=0.461 Mean (SD) 6.8 (14.1) 7.8 (19.3) 7.7 (18.6)
Median (range) 2.75 (0.1–70) 3 (0.1–180) 3 (0.1–180)
Frequency of seizures / month after Tx in 2006 N 35 175 210
p=0.093 Mean (SD) 0.4 (0.8) 0.8 (2.6) 0.8 (2.4)
Median (range) 0 (0–3) 0.2 (0–29.5) 0.2 (0–29.5)
Compliance with Tx Compliant N (%) 14 (42.4) 95 (53.7) 109 (51.9)
p=0.259 Non-compliant N (%) 19 (57.6) 82 (46.3) 101 (48.1)
Reduction of seizure frequency in 2006 in percent N 32 169 201
All PWE Mean (SD) 90.2 (21.9) 81.6 (29.5) 82.9 (28.5)
p=0.081 Median (range) 100 (0–100) 97.8 (0–100) 99.6 (0–100)
Reduction of seizure frequency in 2006 in percent N 16 80 96
Non compliant Mean (SD) 82.2 (29.0) 73.0 (34.1) 74.6 (33.3)
p=0.362 Median (range) 96.5 (0–100) 87.0 (0–100) 89.3 (0–100)
Reduction of seizure frequency in 2006 in percent N 14 89 103
All Compliant: Mean (SD) 98.6 (3.6) 89.2 (22.1) 90.5 (20.8)
p=0.046 Median (range) 100 (89–100) 100 (0–100) 100 (0–100)
Reduction of seizure frequency in 2006 in percent N 9 65 74
Compliant on Carbamazepine Mean (SD) 99.0 (2.8) 89.2 (21.7) 90.4 (20.6)
p=0.069 Median (range) 100 (92–100) 98.8 (0–100) 100 (0–100)
Reduction of seizure frequency in 2006 in percent N 5 21 26
Compliant on Phenobarbitone Mean (SD) 97.8 (5.0) 87.9 (24.7) 89.8 (22.5)
p=0.294 Median (range) 100 (89–100) 100 (0–100) 100 (0–100)
Family history of seizures n=212; p=0.688 N (%) 11 (31.4) 50 (28.2) 61 (28.8)
PPH of depression n=211; p=0.224 N (%) 0 (0.0) 12 (6.8) 12 (5.7)
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The seizure frequencies, compliance with anti-epileptic drug
(AED) and reduction of seizure frequency after treatment in PWE
with and without NCC are listed in Table 1. There was a trend
towards generalised epilepsies without focal neurological signs that
started outside the age range of idiopathic epilepsies (implying that
there may be structural brain damage) and generalised epilepsies
with clear focal signs being commoner in the NCC group. On the
other hand, idiopathic epilepsies, which are usually generalised
seizures starting within a specific age range, and epilepsies
associated with brain damage were more frequent in PWE
without NCC.
T h ec o m p l i a n c ew i t hA E Dw a ss l i g h t l yb e t t e ri nt h eg r o u p
without NCC, although this did not reach significance. The
administration of the type of AED was similar in both groups.
Among compliant PWE taking their AED regularly, the group
of PWE with NCC had a significantly higher reduction of
seizures (Table 1). The percentage of people without seizures
since their last visit was higher among compliant PWE
(compliant: 54.1%, 59/109; non-compliant: 40.6%, 41/101;
Fisher’s exact test p=0.054). Dividing compliant and non-
compliant PWE according to the presence of NCC a higher
percentage of people without seizures was observed among
compliant PWE with NCC compared to those without NCC
(compliant: 78.6%, 11/14 PWE with NCC, 50.5%, 48/95 PWE
without NCC, Fisher’s exact test p=0.082; non-compliant:
42.1%, 8/19 PWE with NCC, 40.2%, 33/82 PWE without
NCC, p=1.000), although the result did not reach significance.
In terms of past psychiatric history, family history of seizures
and educational level no significant differences were found. For
more details see Table 1.
Risk Factors Associated with Neurocysticercosis
Number of people in household as an indicator of crowding,
number of pigs at home, close contact with pigs and use of latrines
as possible risk factors for NCC were not significantly associated
with NCC. However, the percentage of people who consumed
pork was significantly higher in the group of people with NCC
(Table 2).
Serological Analysis of Serum Samples
Allsampleswhich were positive usingthe CWBwere also positive
using the CDC EITB. Additionally, seven samples that were
negative in the CWB were positive in the CDC EITB, which was
statistically significant (McNemar, p=0.016). Five of these seven
had multiple calcified lesions highly suggestive of NCC, one had
multiple calcified lesions and one hypodense lesion and one had a
normal CT. The percentage of a positive CDC EITB result in the
group of PWE with NCC calcifications (=highly suggestive of
NCC) was much higher (52.2%, 12/23) than the percentage of the
same group tested with the CWB (13.3%, 2/15; ‘‘sensitivity’’, if CT
wasusedasa goldstandard).Even withthesmallnumberofsamples
that was analysed in both labs (n=15), this approached significance
(negative in both tests: 8, positive in both tests: 2, CWB negative,
CDC EITB positive: 5; McNemar, p=0.063). Concerning people
witha normalCT,all samples (20/20) werenegative withtheCWB,
whereas 91.3% (42/46) were negative with the CDC EITB
(‘‘specificity’’, if CT was used as gold standard). The results of
CSF samples were identical in CWB and CDC EITB.
Diagnosis of Neurocysticercosis
Using the results of the CDC EITB as the serological gold
standard, as suggested by Del Brutto et al. [21,22], 17 people were
Table 2. Frequency of potential risk factors of neurocysticercosis in people with epilepsy with and without neurocysticercosis.
Potential risk factors of NCC PWE with NCC PWE without NCC Total
Number of people in household N 35 174 209
p=0.856 Mean (SD) 6.9 (3.0) 7.4 (4.2) 7.3 (4.0)
Median (range) 6 (2–13) 7 (1–30) 7 (1–30)
Number of pigs in household N 35 174 209
p=0.370 Mean (SD) 1.3 (2.0) 1.1 (2.0) 1.1 (2.0)
Median (range) 0 (0–10) 0 (0–10) 0 (0–10)
Close contact with pigs n=212; p=0.351 N (%) 17 (48.6) 70 (39.5) 87 (41.0)
Pork consumption n=209; p=0.001 N (%) 34 (97.1) 128 (73.6) 162 (77.5)
Use of latrine n=209; p=1.000 N (%) 34 (97.1) 169 (97.1) 203 (97.1)
PWE... People with epilepsy, NCC... Neurocysticercosis.
doi:10.1371/journal.pntd.0001185.t002
Characteristics PWE with NCC PWE without NCC Total
PPH of psychotic episodes n=212; p=1.000 N (%) 1 (2.9) 5 (2.8) 6 (2.8)
PPH of mental retardation n=212; p=1.000 N (%) 4 (11.4) 23 (13.0) 27 (12.7)
1)Gwa...Generalised seizures that started within a specific age range (seizures most likely due to idiopathic epilepsy), Gfs...Generalised seizures with obvious focal
neurological signs, Goa...Generalised seizures that started outside the age range of idiopathic epilepsies but without any obvious sign or history of an underlying
cause, Gbd...Generalised seizures with more widespread brain damage, Tt...Two different seizure types, U...Unclassified epileptic seizures; for more details see Winkler
et al. [19] PWE... People with epilepsy, NCC... Neurocysticercosis, Tx... Anti-epileptic treatment, PPH... Past psychiatric history.
doi:10.1371/journal.pntd.0001185.t001
Table 1. Cont.
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the CWB had been used (Table 3). Similarly, the percentage of
PWE with probable and definitive NCC was 16.5% (35/212)
using the CDC EITB results, compared to 13.7% (29/212) if the
CWB was used.
Association of Antibody Test Results with Number and
Type of Neurocysticercosis Lesions
The results of both antibody tests together with the number of
total NCC lesions on CT, including cysts and calcifications, are
listed in Table 4. The number of NCC lesions was significantly
associated with a positive serum antibody result (Mann-Whitney-
U, CWB: p=0.006, CDC EITB: p,0.001). People with more CT
lesions had a higher chance of a positive antibody result. Probably
due to the low number of samples, there was no significant
association in CSF (Mann-Whitney-U, p=0.537).
Active NCC lesions were significantly associated with a positive
antibody result in both tests for serum and CSF (Fisher’s exact test,
Serum CWB: p=0.002; Serum CDC EITB: p=0.022; CSF both
tests: p=0.015, see Table 4). The prevalence of cysticercosis
antibodies detected by the CDC EITB among people with single
lesions was 22.2% (2/9, ‘‘sensitivity’’, if CT was used as gold
standard). CWB was not performed in people with single lesions
(Table 4). People with at least two lesions, when analysed with
CDC EITB and CWB had antibodies in 65.4% (17/26) and 30%
(6/20), respectively (‘‘sensitivity’’, if CT was used as a gold
standard). Looking at individuals with a positive CSF result, all
corresponding serum samples were positive in the CDC EITB and
four out of five were positive in the CWB.
Discussion
General Aspects
To our knowledge this is the first study that systematically
compares demographic data and clinical characteristics of PWE
with and without NCC in sub-Saharan Africa. A differentiation
between these two groups is important not only because of the
possible treatment of active NCC, but also because of prevention
and disease control programs for NCC.
There are several limitations of our study. The diagnosis of
epilepsy was made up to three years prior to the performance of
the CT scan and the collection of specimens. Hence the number of
people with active NCC might be underestimated. Due to lack of
EEG the diagnosis of epilepsy is based on clinical examination and
thorough interviews of patients and relatives. Epileptic seizures
that appear generalized may have a short focal start that clinically
goes unnoticed. Simple partial seizures may not be diagnosed,
because patients do not report to the hospital. As to serology, it
would have been preferable, if cysticercosis serology had been
performed in all PWE. This unfortunately was not possible in our
study.
Clinical Characteristics of People with Epilepsy and
Neurocysticercosis
Demographic data about PWE in low income countries is
limited. Singhvi et al. described the patterns of patients (n=100)
with intractable epilepsy at a tertiary center in India. All patients
received at least two AEDs. In their study, the mean age was 23.2
years with a mean duration of seizures of 11.4 years and their
Table 3. Diagnosis of neurocysticercosis according to Del Brutto et al. using two different antibody tests.
Diagnosis of NCC* Commercial Western blot CDC EITB
n Positive Negative nt n Positive Negative nt
No NCC 183 (86.3%) 0 20 163 177 (83.5%) 0 47 130
Probable NCC 22 (10.4%) 0 13 9 18 (8.5%) 6 11 1
Definitive NCC 7 (3.3%) 6 1 0 17 (8.0%) 17 0 0
*According to NCC diagnostic criteria of Del Brutto et al. [21,22]
NCC... Neurocysticercosis, CDC EITB... Electroimmunotransfer blot developed by the Centers for Disease Control and Prevention, Atlanta, GA, USA, nt... Not tested.
doi:10.1371/journal.pntd.0001185.t003
Table 4. Number and activity of neurocysticercosis lesions on cerebral computed tomography scan and cysticercosis antibody
results.
Number of NCC EITB CDC Commercial Western Blot CSF both tests
lesions on CT scan* Negative Positive Negative Positive Negative Positive
0 42 (91.3%) 4 (8.7%) 20 (100%) 0 (0.0%) 0 0
1 7 (77.8%) 2 (22.2%) 0 0 0 0
2–4 5 (45.5%) 6 (54.5%) 6 (100%) 0 (0.0%) 3 (100%) 0 (0.0%)
$5 4 (26.7%) 11 (73.3%) 8 (57.1%) 6 (42.9%) 3 (37.5%) 5 (62.5%)
Total 58 (71.6%) 23 (28.4%) 34 (85.0%) 6 (15.0%) 6 (54.5%) 5 (45.5%)
Activity of NCC lesions on CT scan
Inactive 16 (55.2%) 13 (44.8%) 13 (92.9%) 1 (7.1%) 6 (85.7%) 1 (14.3%)
Active 0 (0%) 6 (100%) 1 (16.7%) 5 (83.3%) 0 (0%) 4 (100%)
*Including active and inactive lesions; NCC... Neurocysticercosis, CDC EITB... Electroimmunotransfer blot developed by the Centers for Disease Control and Prevention, in
Atlanta, GA, USA, CSF... Cerebrospinal fluid, CT...Computed tomography.
doi:10.1371/journal.pntd.0001185.t004
Characteristics of Epilepsy and Neurocysticercosis
www.plosntds.org 6 June 2011 | Volume 5 | Issue 6 | e1185mean seizure frequency was 12.4 seizures per month [29]. In our
study, the mean age was higher with 28.2 years and the average
age at first seizure was 17.7 years. The older age of our study
population could be explained by the exclusion of children
younger than ten years at time of diagnosis. The mean seizure
frequency in our drug naı ¨ve PWE with 7.7 seizures per month was
lower compared to the study of Singhvi et al.
The mean age of PWE with NCC in our study (32.5 years) is
comparable to the mean age (28.6 years) of people with NCC in a
large retrospective study of people with NCC treated in Houston,
Texas, that included 202 individuals mainly presenting with
seizures [30]. In our study, there was a trend that PWE with NCC
were older and that they had their first seizure later compared to
PWE without NCC. This may suggest that NCC should be
considered as an underlying cause of epilepsy especially among
PWE with a late onset of seizures. Other studies reported that
NCC is the cause of late onset epilepsy in up to 50% [31–34].
However, a recent review revealed similar percentages of NCC
associated epilepsy in the age group below 20 years and that of 20–
54 years of age [10]. These data suggest that NCC has also to be
considered as a cause of epilepsy in young PWE.
In our study, PWE with active NCC were significantly older
than PWE with inactive NCC, which might be explained by a
different immune response to the infestation with age. Porcine
cysticercosis was first detected in our study area in the late 1980s
and previously pig husbandry was not common [12]. If infestations
caused more calcifications in younger people, the lower number of
calcifications among older people could also be explained by the
absence of NCC before the introduction of pig husbandry.
The gender in our study population of PWE was equally
distributed, which is in accordance with another study in Tanzania
[35] and with the conclusion of reviews about the prevalence of
epilepsy in Asia [36] and sub-Saharan Africa [1], which did not
find a significant difference regarding gender. In our study slightly
more males had NCC, a result similar to the one reported by
Nicoletti et al., who diagnosed 21 males and 14 females with NCC
among 124 PWE [34].
It is remarkable that, although PWE with NCC were less
compliant, they had a lower seizure frequency. The reduction of
seizure frequency in compliant PWE was significantly higher in
PWE with NCC compared to those without NCC. 78.6% of
compliant PWE with NCC had no seizures, whereas this was only
the case in 50.5% of compliant PWE without NCC. These
observations not only suggest that the frequency of seizures due to
NCC seems to decline faster over time, but also that anti-epileptic
treatment with carbamazepine or phenobarbitone, which is
available in most low income countries, is very efficient in
controlling seizures due NCC. Del Brutto et al., who investigated
203 PWE with NCC, reported a similar seizure control rate of
83% [37].
The reason for the higher percentage of NCC among people of
the Iraqw tribe might be that according to our observation pig
farming is more common in that tribe compared to other tribes.
This difference might disappear in future, because tribes are
intermingling and pig husbandry seems to become abundant in all
tribes.
The past psychiatric history and family history of seizures seem
to be similar in PWE with and without NCC. In our study, the
only significant risk factor associated with NCC was pork
consumption. In this context, we want to stress that cysticercosis
is a faecal-oral infestation and pork consumption is not a
prerequisite for cysticercosis. The consumption of undercooked
pork or the handling of infected pig meat could lead to a
tapeworm carrier in the household. Lescano et al. showed that
there is a significant cysticercosis seroprevalence gradient around a
tapeworm carrier and that the risk for cysticercosis is high, if there
is a tapeworm carrier in the household [38]. Other factors related
to social status such as number of people per household or
educational level and also pig contact or number of pigs per
household were not significantly associated with NCC. The use of
latrines, which has been identified as a risk factor for porcine
cysticercosis [39], was almost omnipresent in our study population.
The number of people who did not use a latrine (6/209) was too
low to identify significant differences.
Antibody Tests for Cysticercosis in People with Epilepsy
and Neurocysticercosis
It is difficult to define sensitivity and specificity of serological
tests for cysticercosis, because the gold standard for the diagnosis
of NCC is not well defined. Probably the best available single
examination to diagnose NCC in low income countries is a CT
scan. Taking the CT result as a gold standard, the comparison
between the two antibody tests for cysticercosis revealed a
difference mainly in terms of sensitivity. Especially among people
with lesions highly suggestive of NCC, which are mainly multiple
calcified lesions, the CDC EITB had a higher sensitivity than the
CWB. Antibodies were detected in 52.2% and 13.3% with the
CDC EITB and the CWB, respectively. However, sensitivity was
low compared to other studies that reported a sensitivity of 60% to
89% in sera with only calcified cysts [40,41]. Rajshekhar et al.,
who studied NCC and epilepsy in India, showed a positive EITB
result in 26.1% (12/46) of PWE with NCC lesions on CT scan [7].
This relatively low number could be explained by the high
percentage of people with only one or two calcifications (81.3%).
In Peru, Montano et al. detected antibodies in 46.7% (7/15) of
PWE with NCC lesions on CT scan. The type of lesions however
was not specified [6]. In active lesions, where the CDC EITB
detected antibodies in all six samples and the CWB in five of six,
the number of samples was too low to show significant differences.
Our results confirm the high sensitivity of the CDC EITB in
people with more than one viable NCC cysts [28,40]. As expected
the total number of active and inactive NCC lesions was positively
correlated with a positive antibody result in both tests. It seems
that a higher burden of disease leads more often to a detectable
antibody response. When looking at PWE with normal CT, it
seems that the specificity of the CDC EITB (91.3%) is lower
compared to the CWB (100%). However, it has to be considered
that cysticercosis may be present in other organs such as eye and
subcutaneous/muscular tissue or that calcifications smaller than
10 mm may be missed because of the thickness of CT slices. The
specificity of the EITB is very high, near 100%, with only a few
anecdotal reports [42,43] of false positive results since the time the
test was introduced in 1989. Therefore, it seems probable that the
four PWE with a positive CDC EITB and normal CT scan may
have had some exposure to T. solium larvae in the past or may
harbour cysts in other organs than the brain.
The analysis of CSF with CDC EITB did not give additional
information regarding the diagnosis of NCC, because all CSF
positive cases had also positive serum samples. Our results are in
accordance with the study of Proan ˜o-Narvaez et al, in which
analysis of serum and CSF samples with a EITB for cysticercosis
were equally sensitive and specific [44]. We conclude that an
analysis of CSF may only be indicated, if a quantitative test is used
in order to calculate a specific T. solium antibody index of a serum/
CSF pair.
In summary, our study compares demographic and clinical
characteristics of PWE with and without NCC in rural northern
Tanzania, showing that PWE with NCC tend to be older with a
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www.plosntds.org 7 June 2011 | Volume 5 | Issue 6 | e1185later onset of seizures compared to those without NCC. Seizure
frequency in compliant PWE with NCC, using AEDs available on
site, seems to respond better than in compliant PWE without
NCC. The only risk factor for NCC that could be identified is
consumption of pork. In addition, the sensitivity and specificity of
a commercially available western blot and the CDC EITB was
tested in PWE with NCC showing a higher sensitivity of the latter,
especially in PWE with calcifications.
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